Direct Medical Care Costs Among Pegylated Interferon Plus Ribavirin-Treated and Untreated Chronic Hepatitis C Patients

By Solomon M.  

Digestive Diseases and Sciences, Vol. 56, Iss. 10, 2011-10 ,pp. : 3024-3031

Springer Publishing Company

Access to resources Recommend Favorite

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

By Nakagawa Mina   Sakamoto Naoya   Ueyama Mayumi   Mogushi Kaoru   Nagaie Satoshi   Itsui Yasuhiro   Azuma Seishin   Kakinuma Sei   Tanaka Hiroshi   Enomoto Nobuyuki   Watanabe Mamoru  

Journal of Gastroenterology, Vol. 45, Iss. 6, 2010-06 ,pp. : 656-665

Springer Publishing Company

Access to resources Recommend Favorite

Acute septic shock during pegylated-interferon and ribavirin therapy in a patient with chronic hepatitis C who underwent aortic graft replacement

By Kobayashi Yoshinao  

Clinical Journal of Gastroenterology, Vol. 4, Iss. 3, 2011-06 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C

By Younossi Zobair   McCullough Arthur   Barnes David   Post Anthony   Ong Janus   O’shea Robert   Martin Lisa   Bringman Diane   Farmer Denise   Levinthal Gavin   Mullen Kevin   Carey William   Tavill Anthony   Ferguson Roy   Gramlich Terry  

Digestive Diseases and Sciences, Vol. 50, Iss. 5, 2005-05 ,pp. : 970-975

Springer Publishing Company

Access to resources Recommend Favorite

Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C

By Tohra S.  

Digestive Diseases and Sciences, Vol. 56, Iss. 8, 2011-08 ,pp. : 2449-2455

Springer Publishing Company

Access to resources Recommend Favorite